Biota's influenza drug fails in mid-stage study

Fri Aug 1, 2014 7:10am EDT

Aug 1 (Reuters) - Biota Pharmaceuticals Inc said its experimental influenza drug failed to meet the main goal in a mid-stage study.

The drug, Laninamivir octanoate, is undergoing development to treat influenza A and B infections. (Reporting by Natalie Grover in Bangalore; Editing by Savio D'Souza)

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.